Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis

Allergy and Asthma Proceedings

Volumn 35, Issue 4, 2014, Pages 278-287

  Zhang, Hong Ping ^a   Jia, Chun E ^a   Lv, Yan ^a   Gibson, Peter Gerard ^a,b   Wang, Gang ^a  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MONTELUKAST; ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE;

ADD ON THERAPY; ADULT DISEASE; ADVERSE OUTCOME; ALLERGIC RHINITIS; ARTICLE; ASTHMA; ATTRIBUTABLE RISK; BRONCHITIS; CLINICAL ASSESSMENT; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; FOLLOW UP; FORCED EXPIRATORY VOLUME; HOARSENESS; HOSPITALIZATION; HUMAN; INFLUENZA; INSOMNIA; LUNG FUNCTION TEST; META ANALYSIS; NAUSEA; NUMBERS NEEDED TO TREAT; OROPHARYNX CANDIDIASIS; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINUSITIS; SORE THROAT; SYSTEMATIC REVIEW; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; TREATMENT OUTCOME;

ACETATES; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; LEUKOTRIENE ANTAGONISTS; QUINOLINES; TREATMENT OUTCOME;

EID: 84904974327     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2014.35.3745     Document Type: Article

References (51)

1. Jackson DJ, Sykes A, Mallia P, and Johnston SL. Asthma exacerbations: Origin, effect, and prevention. J Allergy Clin Immunol 128:1165-1174, 2011.
2. Ostrom NK, Parsons JP, Eid NS, et al. Exercise-induced bronchospasm, asthma control, and obesity. Allergy Asthma Proc 34:342-348, 2013.
3. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Revised 2010. Available online at www.ginasthma.org/ReportItem.asp?l1=2&l2=2&intId=9; accessed December 12, 2011.
4. Reddel HK, Taylor DR, Bateman ED, et al.; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 180:59-99, 2009.
5. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337:1405-1411, 1997.
6. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med. 164:1392-1397, 2001. (Pubitemid 33124016)
7. Sabin BR, Avila PC, Grammer LC, and Greenberger PA. Chapter 15: Lessons learned from clinical trials of asthma. Allergy Asthma Proc 33(suppl 1):S51-S54, 2012.
8. Ducharme FM. Inhaled glucocorticoid versus leukotriene receptor antagonists as single agent asthma treatment: Systematic review of current evidence. BMJ 326:621, 2003.
9. Guyatt GH. Methodologic problems in clinical trials in heart failure. J Chronic Dis 38:353-363, 1985. (Pubitemid 15044153)
10. Higgins JPT, and Green S. Cochrane handbook for systematic reviews of interventions. Available online at www.cochrane-handbook.org; accessed March 13, 2011.
11. GRADE working group. www.gradeworkinggroup.org/index.htm.
12. Cochrane Informatics & Knowledge Management Department. GRADEpro. [Computer program]. Version 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008. www.ims.cochrane.org/revman/gradepro.
13. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Montelukast Clinical Research Study Group. Arch Intern Med 158:1213-1220, 1998.
14. Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J 11:1232-1239, 1998. (Pubitemid 28298582)
15. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma, a randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 130:487-495, 1999. (Pubitemid 29135801)
16. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 160:1862-1868, 1999. (Pubitemid 30004688)
17. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 106:1088-1095, 2000. (Pubitemid 32006262)
18. Busse W, Raphael GD, Galant S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial. J Allergy Clin Immunol 107:461-468, 2001. (Pubitemid 32210026)
19. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 120:423-430, 2001. (Pubitemid 32881257)
20. Calhoun WJ, Nelson HS, Nathan RA, et al. Comparison of fluticasone propionate - salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta2-agonists alone. Am J Respir Crit Care Med 164:759-763, 2001. (Pubitemid 32881910)
21. Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 110:847-854, 2002. (Pubitemid 36005870)
22. Meltzer EO, Lockey RF, Friedman BF, et al.; Fluticasone Propionate Clinical Research Study Group. Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma. Mayo Clin Proc 77:437-445, 2002. (Pubitemid 34465151)
23. Pearlman DS, White MV, Lieberman AK, et al. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann Allergy Asthma Immunol 88:227-235, 2002. (Pubitemid 34165037)
24. Vaquerizo MJ, Casan P, Castillo J, et al.; CASIOPEA (Capacidad de Singulair Oral en la Prevencion de Exacerbaciones Asmaticas) Study Group. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 58:204-210, 2003.
25. Ringdal N, Eliraz A, Pruzinec R, et al.; International Study Group. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 97:234-241, 2003. (Pubitemid 36266879)
26. Grosclaude M, Cerruti JL, Delannay B, et al. A fixed combination of fluticasone and salmeterol permits better control of asthma than a beclomethasone dipropionate and montelukast combination. Eur Ann Allergy Clin Immunol 35:356-362, 2003. (Pubitemid 37553420)
27. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: One year, double blind, randomised, comparative trial. BMJ 327:891-896, 2003.
28. Price DB, Hernandez D, Magyar P, et al.; Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 58:211-216, 2003. (Pubitemid 36307998)
29. Ilowite J, Webb R, Friedman B, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: A randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 92:641-648, 2004. (Pubitemid 39243154)
30. American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 175:235-242, 2007.
31. Deykin A, Wechsler ME, Boushey HA, et al.; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Combination therapy with a long-acting beta-agonist and a leukotriene antagonist NOT in moderate asthma. Am J Respir Crit Care Med 175:228-234, 2007. (Pubitemid 46203125)
32. Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 364:1695-1707, 2011.
33. Ferreira MB, Santos AS, Pregal AL, et al. Leukotriene receptor antagonists (Montelukast) in the treatment of asthma crisis: Preliminary results of a double-blind placebo controlled randomized study. Allerg Immunol (Paris) 33:315-318, 2001.
34. Camargo CA Jr, Smithline HA, Malice MP, et al. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 167:528-533, 2003.
35. Cýllý A, Kara A, Ozdemir T, et al. Effects of oral montelukast on airway function in acute asthma. Respiratory Medicine 97:533-536, 2003. (Pubitemid 36519525)
36. Camargo CA Jr, Gurner DM, Smithline HA, et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol 125:374-380, 2010.
37. Ramsay CF, Pearson D, Mildenhall S, and Wilson AM. Oral montelukast in acute asthma exacerbations: A randomised, double-blind, placebo-controlled trial. Thorax 66:7-11, 2011.
38. Adachi M, Taniguchi H, Tohda Y, et al. The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in Japanese patients. J Asthma 49:649-656, 2012.
39. Murphy KR, Meltzer EO, Blaiss MS, et al. Asthma management and control in the United States: Results of the 2009 Asthma Insight and Management survey. Allergy Asthma Proc 33:54-64, 2012.
40. Guan W, Zheng J, Gao Y, et al. Leukotriene D4 and methacholine bronchial provocation tests for identifying leukotriene-responsiveness subtypes. J Allergy Clin Immunol 131:332-338.e1-4, 2013.
41. Matsuse H, and Kohno S. Leukotriene receptor antagonists pranlukast and montelukast for treating asthma. Expert Opin Pharmacother 15:353-363, 2014. (Epub ahead of print December 19, 2013.)
42. Sadatsafavi M, Lynd L, Marra C, et al. Comparative outcomes of leukotriene receptor antagonists and long-acting beta-agonists as add-on therapy in asthmatic patients: A populationbased study. J Allergy Clin Immunol 132:63-69, 2013.
43. van der Wiel E, ten Hacken NH, Postma DS, and van den Berge M. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: A systematic review. J Allergy Clin Immunol 131:646-657, 2013.
44. Pisi R, Tzani P, Aiello M, et al. Small airway dysfunction by impulse oscillometry in asthmatic patients with normal forced expiratory volume in the 1st second values. Allergy Asthma Proc 34:e14-e20, 2013.
45. Macklem PT, and Mead J. Resistance of central and peripheral airways measured by a retrograde catheter. J Appl Physiol 22:395-401, 1967.
46. Barnes PJ, Nicolini G, Bizzi A, et al. Do inhaled corticosteroid/long- acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. Allergy Asthma Proc 33:140-144, 2012.
47. Tufvesson E, Nihlberg K, Westergren-Thorsson G, and Bjermer L. Leukotriene receptors are differently expressed in fibroblast from peripheral versus central airways in asthmatics and healthy controls. Prostaglandins Leukot Essent Fatty Acids 85:67-73, 2011.
48. Watts K, and Chavasse RJ. Leukotrience receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst Rev 5:CD006100, 2012.
49. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: Systematic review of current evidence. BMJ 324:1545, 2002.
50. Sin DD, Man J, Sharpe H, et al. Pharmacological management to reduce exacerbations in adults with asthma: A systematic review and meta-analysis. JAMA 292:367-376, 2004. (Pubitemid 38944262)
51. Amlani S, Nadarajah T, and McIvor RA. Montelukast for the treatment of asthma in the adult population. Expert Opin Pharmacother 12:2119-2128, 2011.